Summit Asset Management has sold its investment (29.1%) in Medical Equipment Solutions Limited (MESL) to Amethyst Radiotherapy, Europe’s fastest growing private cancer treatment institution as part of the sale of the entirety of the business enabling Amethyst to expand its European operations into the UK.
MESL is a specialist provider of intracranial radiation treatments using the Gamma Knife* platform, a non-invasive stereotactic radiosurgery platform that involves no scalpel or incision. With two centres in the UK, the Queen Square Radiosurgery Centre in London and the Thornbury Radiosurgery Centre in Sheffield, MESL is a key NHS partner in the delivery of specialist radiotherapy treatments.
Amethyst Radiotherapy now operates twelve radiotherapy centres across six countries with a further twenty either in planning and/or development.
Group CEO, Ludovic Robert, says: “Amethyst Radiotherapy aims to build on the established reputation of Queen Square Radiosurgery Centre, London, and the Thornbury Radiosurgery Centre in Sheffield to provide the best possible, evidence based treatment for patients with previously hard to treat brain lesions.”
Adding: “Amethyst is rigorously focused on delivering the highest quality of service for patients, working in close partnership with leading NHS Centres of Excellence, Neurosurgeons and Oncologists as well as private payors and providers across the wider health economy.” Amethyst expects to further develop its service footprint across the UK. Amethyst Radiotherapy has appointed Stefan Doroszkowski to lead the UK business roll-out. Stefan has worked +25 years across the industry for a wide range of public and private payors and providers.
* Gamma Knife is a registered trade-mark of Elekta. All rights reserved
